Megestrol Acetate in Relapsed Carcinoma of Prostate

British Journal of Urology

Volumn 65, Issue 3, 1990, Pages 275-277

  DANIEL, F ^a   MacLEOD, P M ^a   TYRRELL, C J ^a  

^a Plymouth General Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; MEGESTROL ACETATE;

ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CARCINOMA;

CARCINOMA; CLINICAL TRIALS; DIETHYLSTILBESTROL; GONADORELIN; HUMAN; MALE; MEGESTROL; MEGESTROL ACETATE; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 0025304484     PISSN: 00071331     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.1990.tb14726.x     Document Type: Article

References (34)

1. Hormone manipulation for palliative treatment of advanced prostatic carcinoma
2. Oestrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo
3. Megestrol acetate used as primary hormonal in stage D prostatic cancer
4. Adrenalectomy and hypophysectomy for prostatic cancer
5. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate
6. Phase II study of megestrol acetate for metastatic carcinoma of the prostate
7. Antiovulatory and other biological properties of megestrol acetate 172‐acetoxy‐6 methyl pregna 4:6., diene‐3:20‐dione (B.D.H. 1298)
8. Therapeutic approaches in prostatic cancer
9. Clinical effect of aminoglutethimide, medical adrenalectomy in treatment of 43 patients with advanced prostatic carcinoma
10. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer
11. Treatment of advanced cancer of prostate with megestrol acetate
12. Aminoglutethimide in advanced prostatic carcinoma
13. Megestrol acetate for treatment of advanced carcinoma of the prostate
14. National randomized study of chemotherapeutic agents in advanced prostatic carcinoma. A progress report
15. Medical progress: prostatic carcinoma
16. New approach in the treatment of prostate cancer. Complete instead of partial withdrawal of androgens
17. Response criteria for the prostate of the USA National Prostatic Cancer Project
18. Treatment of advanced prostatic cancer, resistant to conventional therapy with aminoglutethimide
19. Endocrine control of prostate carcinoma. Clinical and statistical survey of 1818 cases
20. Carcinoma of the prostate. The therapeutic dilemma
21. Androgen suppression by Hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer
22. Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer
23. Treatment of stage IV carcinoma of the prostate
24. Aminoglutethimide therapy for advanced carcinoma of the prostate
25. The patient, disease status and treatment options for prostate cancer Stage D and D2
26. Prostatic carcinoma treated at Categorial Center, clinical and pathological observations
27. Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy
28. Plasma testosterone and androstenedione after orchiectomy in prostatic adenocarcinoma
29. Cyproterone acetate in the treatment of advanced carcinoma of the prostate
30. SCH 13521 in the treatment of advanced carcinoma of the prostate
31. Carcinoma of the prostate. Treatment comparisons
32. Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate
33. Experience and treatment of prostatic carcinoma with cyproterone acetate